DOSAGE D'ANTICORPS SÉRIQUES PERMETTANT DE DÉTERMINER LA PROTECTION CONTRE LE PALUDISME ET VACCINS SOUS-UNITAIRES DIRIGÉS CONTRE LES STADES PRÉ-ÉRYTHROCYTAIRES
Sanaria Inc.;Antigen Discovery Inc.;The United States of America, represented by the Secretary, Department of Health and Human Services
发明人:
申请号：
EP14839238.4
公开号：
EP3039421A4
申请日:
2014.09.02
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
Disclosed herein are diagnostic assays for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such assays are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. The assays comprise the use of proteomes representing at least 50% of Pf, preferably coupled to a solid phase as a fixed array. The arrays are used to probe the sera of human subjects, particularly subjects of human clinical trials of whole parasite malaria vaccines as well as public health vaccination campaigns. Serum samples with antibody profiles most strongly reactive in multiplex to CSP and MSP5 demonstrate a sensitivity of from 92% to 100% and a specificity of from 84% to 89%.
